Stockley, Robert A. http://orcid.org/0000-0003-3726-1207
Pye, Anita
De Soyza, Joshua
Turner, Alice M.
Miravitlles, Marc
Torres-Duran, María
Tanash, Hanan
Rodríguez-García, Carlota
López-Campos, José Luis
Chlumsky, Jan
Guimaraes, Catarina
Rodríguez-Hermosa, Juan Luis
Corsico, Angelo
Martinez-González, Cristina
Hernández-Pérez, José María
Bustamante, Ana
Parr, David G.
Casas-Maldonado, Francisco
Hecimovic, Ana
Janssens, Wim
Lara, Beatriz
Barrecheguren, Miriam
González, Cruz
Stolk, Jan
Clarenbach, Christian F.
,
Article History
Received: 27 February 2023
Accepted: 12 July 2023
First Online: 12 August 2023
Declarations
:
: EARCO received ethics approval in individual countries and all participants gave written informed consent for their data to be included in the EARCO database. In UK the study was approved by London-Camden and Kings Cross Research Ethics Committee, REC Ref: 19/LO/1106.
: Not applicable.
: Marc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi, Zambon and Grifols and research grants from Grifols. Alice M Turner has received either grants or speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, CSL Behring, Takeda, Vertex and Grifols Biotherapeutics. Robert A Stockley has received research grants from Mereo BioPharma and CSL Behring, consulting fees from Mereo BioPharma, CSL Behring, Vertex, Inhibrx and chairs the DSMB for Takeda.